Olympus (OTCMKTS:OCPNY – Get Free Report) is one of 515 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Olympus to related businesses based on the strength of its valuation, risk, earnings, institutional ownership, analyst recommendations, dividends and profitability.
Volatility & Risk
Olympus has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Olympus’ competitors have a beta of 2.56, suggesting that their average share price is 156% more volatile than the S&P 500.
Profitability
This table compares Olympus and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Olympus | 13.80% | 24.30% | 9.30% |
| Olympus Competitors | -276.70% | -157.85% | -22.32% |
Dividends
Valuation and Earnings
This table compares Olympus and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Olympus | $7.74 billion | $1.03 billion | 21.95 |
| Olympus Competitors | $1.90 billion | $144.69 million | 8.34 |
Olympus has higher revenue and earnings than its competitors. Olympus is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Olympus and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Olympus | 0 | 0 | 1 | 0 | 3.00 |
| Olympus Competitors | 4183 | 10268 | 17893 | 790 | 2.46 |
As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 33.05%. Given Olympus’ competitors higher possible upside, analysts plainly believe Olympus has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
0.0% of Olympus shares are owned by institutional investors. Comparatively, 40.1% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 14.8% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Olympus beats its competitors on 9 of the 15 factors compared.
Olympus Company Profile
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Olympus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olympus and related companies with MarketBeat.com's FREE daily email newsletter.
